<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03142165</url>
  </required_header>
  <id_info>
    <org_study_id>IM025-001</org_study_id>
    <nct_id>NCT03142165</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of BMS-986263 in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Actual">November 29, 2017</completion_date>
  <primary_completion_date type="Actual">November 29, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>28 days</time_frame>
    <description>measured by incidences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events (SAE)</measure>
    <time_frame>30 days</time_frame>
    <description>measured by incidences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion related reactions</measure>
    <time_frame>28 days</time_frame>
    <description>measured by incidences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormalities in clinical laboratory tests</measure>
    <time_frame>28 days</time_frame>
    <description>measured by incidences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal vital sign measurements</measure>
    <time_frame>28 days</time_frame>
    <description>measured by incidences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal electrocardiogram measurements</measure>
    <time_frame>28 days</time_frame>
    <description>measured by incidences</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination abnormalities</measure>
    <time_frame>28 days</time_frame>
    <description>measured by incidences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>28 days</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>28 days</time_frame>
    <description>Time of maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-T)</measure>
    <time_frame>28 days</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU)</measure>
    <time_frame>28 days</time_frame>
    <description>Area under the concentration-time curve in one dosing interval (multiple dose only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-HALF</measure>
    <time_frame>28 days</time_frame>
    <description>Terminal phase half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLT</measure>
    <time_frame>28 days</time_frame>
    <description>Total body clearance after IV dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AI_AUC</measure>
    <time_frame>28 days</time_frame>
    <description>Accumulation Index, the ratio of AUC(TAU) at steady-state to that after the first dose (Day 15 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-HALFeff_AUC</measure>
    <time_frame>28 days</time_frame>
    <description>Effective elimination half-life that explains the degree of accumulation observed for AUC(TAU) (Day 15 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>28 days</time_frame>
    <description>Trough observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pharmacokinetic (PK) parameters in non-Japanese versus Japanese patients</measure>
    <time_frame>28 days</time_frame>
    <description>Investigation of population specific differences in PK</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>BMS-986263</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986263</intervention_name>
    <description>3 weekly doses of 90 mg infused intravenous administration</description>
    <arm_group_label>BMS-986263</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>50 mg intravenous administration</description>
    <arm_group_label>BMS-986263</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>20 mg intravenous administration</description>
    <arm_group_label>BMS-986263</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy participants as determined by no clinically significant deviation from normal
             in medical history, physical exam, ECGs, and clinical laboratory determinations

          -  Weight within the range of ≥60 and ≤90 kg

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
             the start of study drug

          -  WOCBP must agree to follow instructions for method(s) of contraception for the
             duration of treatment with BMS-986263 (21 days), plus 5 half-lives of BMS-986263 (7.5
             days) plus 30 days (duration of ovulatory cycle) for a total of 90 days post-treatment
             completion

          -  Males who are sexually active with WOCBP must agree to follow instructions for
             method(s) of contraception for the duration of treatment with BMS-986263 (21 days)
             plus 5 half-lives of BMS-986263 (7.5 days) plus the duration of sperm turnover (90
             days) for a total of 118.5 days post-treatment completion. In addition, male
             participants must be willing to refrain from sperm donation during this time.
             Azoospermic males are exempt from contraceptive requirements

        Exclusion Criteria:

          -  History or evidence of active infection and/or febrile illness within 7 days of Study
             Day 1 (e.g., bronchopulmonary, urinary, gastrointestinal, etc.)

          -  History of serious bacterial, fungal, or viral infections that let to hospitalization
             and IV antibiotic treatment within 90 days prior to screening, or any recent serious
             infection requiring antibiotic treatment within 30 days of Study Day 1

          -  History of recurrent or chronic sinusitis, bronchitis, pneumonia, urinary tract
             infection, or skin infection (recurrent or chronic infection is defined as ≥2 episodes
             within a 6 month period)

          -  Active herpes infection, including herpes simplex 1 and 2 and herpes zoster
             (demonstrated on physical examination and/or medical history)

          -  History of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Presence of active tuberculosis (TB), latent TB, or inadequately treated latent or
             active TB

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wcct Global, Llc</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

